ideasIdea
Extend p53 reactivation beyond the Y220C mutation
One faulty version of the p53 guardian protein can now be repaired by a drug that plugs a hole in it. Systematically hunting for similar holes in other faulty versions could help far more patients.
Rezatapopt (PC14586) binds a crevice created by the TP53 Y220C mutation and restores wild-type folding, with responses reported in early trials. Y220C is only around 1 percent of TP53 mutations. A systematic structural and covalent-fragment campaign across the ten commonest TP53 hotspots (R175H, R248Q, R273H, R282W and others), using cryo-EM, deep mutational scanning and AI structure prediction of mutant conformational ensembles, could find analogous pockets or cysteine-reactive sites.
Hypothesis
At least two additional TP53 hotspot mutants have a reproducible small-molecule-stabilisable conformation that restores p53 transcriptional activity in cells by more than 50 percent of wild-type.
Rationale
TP53 is mutated in about half of all cancers; a mutation-specific reactivator strategy is now clinically validated in principle, and the chemistry (covalent stabilisers, chaperone-like binders) is transferable.
What would test it
A three-year structure-first campaign with a public compound and structure release; cell-based p53 reporter and transcriptomic restoration assays as the go/no-go for each hotspot.
Maturity
early clinical
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
6
Bottlenecks it attacks
- The undruggable drivers · The proteins that drive most cancers, such as MYC, mutant p53 and most RAS variants, still have no good drug.